Skip to main content

Lyumjev FDA Approval History

Last updated by Judith Stewart, BPharm on Oct 31, 2022.

FDA Approved: Yes (First approved June 15, 2020)
Brand name: Lyumjev
Generic name: insulin lispro-aabc
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Diabetes, Type 1, Diabetes, Type 2

Lyumjev (insulin lispro-aabc) is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Development timeline for Lyumjev

Oct 14, 2022Approval Lyumjev (insulin lispro-aabc) Injection Approved by U.S. FDA for Children with Diabetes
Aug 16, 2021Approval FDA Approves Lyumjev (insulin lispro-aabc injection) 100 units/mL for Use in Insulin Pumps
Jun 15, 2020Approval FDA Approves Lyumjev (insulin lispro-aabc injection) for Type 1 and Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.